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Development of cardiovascular disorders is associated with various risk factors and 
oxidative stress plays an important role in many of them. Iron-catalysed production of highly 
toxic and reactive hydroxyl radicals may contribute to oxidative stress. Chelation of free iron 
seems to be a promising strategy to prevent the propagation of oxidative stress. However, the 
use of classic iron chelators in pathological conditions without iron overload is associated with 
the risk of toxicity due to the iron depletion. Hence, this study deals with cardioprotective 
properties of iron chelators as well as prochelators derived from them. We focused on 
prochelators with almost no affinity for iron ions until they are activated under disease-specific 
oxidative stress conditions. For a long time, it has been assumed that oxidative stress is also the 
main denominator in an anthracycline-induced cardiotoxicity. However, the previous studies 
suggested alternative mechanism(s). Therefore in the second part of this work, we focused on 
studying the possibilities of pharmacological protection of anthracycline cardiotoxicity using a 
catalytic inhibitors of topoisomerase II and compounds providing nitric oxide and the 
determination of their impact on the antiproliferative efficacy of anthracyclines. 
The results of this study confirm that iron chelators are highly effective protective 
compounds against oxidative stress-induced cardiomyocyte damage, but they also show dose-
dependent toxicity caused by iron depletion. Salicylaldehyde isonicotinoyl hydrazon (SIH) had 
the best ratio of protective effect and inherent toxicity. Prochelators of iron represent promising 
approach to prevent this common limitation of iron chelators. BSIH, the prochelator derived 
from SIH with boronyl protective group, showed the best properties. There was no inherent 
toxicity observed even in long-term experiments and moreover it has significantly prevented 
oxidative damage in cardiomyocytes. We found that BSIH was stable compound, but after 
activation for effective chelator SIH, there was a rapid degradation of the molecule. However, 
the main decomposition product was salicylaldehyde with retained significant chelating ability 
and cardioprotective properties. Prochelator of iron BSIH is therefore a very promising 
compound suitable for further evaluations. 
In the next part, we tried to contribute to the elucidation of mechanisms leading to anthracycline 
cardiotoxicity and to study the possibilities of pharmacological cardioprotection. We were 
unable to confirm the cardioprotective properties of compounds increasing nitric oxide levels; 
neither inorganic nitrates/nitrites, nor molsidomine. In high concentrations, molsidomine 
induced decomposition of anthracyclines. On the other hand, in low concentrations, it enhanced 
their antiproliferative effects. We also examined the cardioprotective effect of catalytic inhibitor 
of topoisomerase II, dexrazoxane, and we found that also other catalytic inhibitors of 
topoisomerase II prevented anthracycline-induced damage of isolated cardiomyocytes while 
they enhanced antiproliferative effects of anthracyclines. Our results therefore support the 
recent theory that the cardioprotective effect of dexrazoxane is rather due to inhibition of 
topoisomerase IIβ in cardiomyocytes than iron chelation. 
 
